Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million in cash, writes John George for the Philadelphia Business Journal.
The deal, valued at $5.85 per share, represents a 17% premium over Nevro’s last closing price.
The acquisition is expected to close in late Q2 2025, pending shareholder and regulatory approvals. Globus, a leader in orthopedic implants and musculoskeletal treatments, aims to expand into the chronic pain market through Nevro’s patented HFX spinal cord stimulation platform.
CEO Dan Scavilla expressed confidence that Globus’ resources will accelerate Nevro’s market penetration, providing superior relief to patients. Founded in 2006, Nevro also offers minimally invasive treatments for sacroiliac joint pain and diabetic neuropathy.
Nevro reported preliminary 2024 revenue of $408–$409 million, down from $425.2 million in 2023. Globus, meanwhile, saw a 60.6% revenue increase, reaching $2.52 billion. The acquisition is expected to push Globus’ annual net sales to $2.8–$2.9 billion.
Globus has over 5,000 employees, while Nevro has approximately 1,100. Morgan Stanley & Co. advised Globus on the deal, with Wyrick Robbins Yates & Ponton as legal counsel. Nevro was advised by BofA Securities Inc., with Latham & Watkins serving as legal counsel.
Read more about Globus Medical’s acquisition of Nevro Corp. in the Philadelphia Business Journal.
